MedTrace Logo

Deacylated Ghrelin and Beta Cell Function

NCT01531283 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-11-14

No results posted yet for this study

Summary

Use of human unacylated ghrelin (UAG, also called des-octanoyl ghrelin) to study physiology in healthy subjects. The proposed research is an investigator-initiated study funded by the National Institutes of Health designed to examine the effect of physiologic levels of UAG on the regulation of glucose homeostasis as well as beta cell function.

Conditions

  • the Diabetic Process

Interventions

DRUG

unacylated ghrelin

IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)

DRUG

acyl ghrelin

IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)

DRUG

combined acyl and desacyl ghrelin

IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)

DRUG

saline

IV, saline, one time, for the duration of the study visit(approximately 5 hours)

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • David Dalessio

    lead OTHER

Study Design

Allocation
RANDOMIZED
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01531283 on ClinicalTrials.gov